Two scientists in Mirai Bio's lab in Cambridge, MA (courtesy Mirai Bio)
September 26, 2024 06:00 AM EDT
Financing
Startups
Manufacturing

Flag­ship launch­es start­up to de­sign and make lipid nanopar­ti­cles for ge­net­ic med­i­cines

Ryan Cross

Senior Science Correspondent

Flag­ship Pi­o­neer­ing is bet­ting $50 mil­lion that it can solve one of ge­net­ic med­i­cine’s biggest prob­lems — how to get the ther­a­pies to the right place …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Bris­tol My­ers and Karuna's schiz­o­phre­nia drug, in mile­stone for psy­chi­a­try

ARCH, biotech's star slug­ger, snags an­oth­er $3B for 13th fund

Up­dat­ed: FDA ad­comm votes to lim­it Op­di­vo, Keytru­da use in stom­ach, esophageal can­cers based on key bio­mark­er

Ex­clu­sive: J&J folds car­dio­vas­cu­lar and meta­bol­ic drug unit

In­sil­i­co Med­i­cine, an ear­ly force in AI-dri­ven drug R&D, lets IPO plans pe­ter out for sec­ond year in a row

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times